Constronics Infra Ltd.
Snapshot View

7.50 ▼0%

12 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.invictameditek.com
Financial Indicators
Market Cap 5.41 Cr.
Earnings per share (EPS) -0.11 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 223.80 Trailing Twelve Months Ending 2021-03
Book Value / Share 0.03 Trailing Twelve Months Ending 2021-03
Price to Book Value 300.00 Calculated using Price: 7.50
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.72 Cr. 7,209,041 Shares
FaceValue 10
Company Profile

Invicta Meditek Limited (Invicta) incorporated in 1992 is a Public Limited company engaged in the manufacture of quality Orthopaedic Implants and Instruments.

Invicta Meditek manufacture the quality Orthopaedic Implants and Instruments. Invicta serves the field of Orthopaedics by supplying products for Total Joint Replacement systems, Trauma Implants and Associated Instruments. The product range also includes implants for Hemi-Arthroplasty, all types of Dynamic Compression and round hole plates, Screws with Cortical, Cancellous profiles, special thread sizes and in all diameters (with and without cannulation) and DHS/ DCS systems. The Joint Replacement Systems for Knee, Hip, Shoulder and Ankle are manufactured under license from Endotec Inc., USA.

Invicta has established a full-fledged machine shop with sophisticated, state of the art machinery required to meet the challenging, stringent quality requirements of the Orthopaedic implants and the high levels of accuracy required for the instruments used in joint replacement and other critical surgical operations.

Invicta lays special emphasis on achieving customer satisfaction by demonstrating the ability to consistently provide products that meet and exceed customer requirements. The Quality Control Department is equipped with the latest tools and instruments maintaining the strict quality standards demanded by the orthopaedic community.

Invicta’s product portfolio includes:-Total Joint Replacements for Knee, Hip, Ankle, Shoulder (under license from Endotec Inc., USA) -trauma implants (plates, screws, nails etc) -associated instrumentation

Product range of the company includes:

  • BP Hiflex Knee
  • Hip Implants
  • Trauma Implants
  • Conventional Implants
  • Instruments

Achievements/ recognition :

  • It is an ISO 13485-2003 & CE certified company.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
1 Month
+9.65%
3 Month
+9.49%
6 Month
+61.29%
1 Year
+88.44%
2 Year
+81.60%
5 Year
+89.87%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -5.20 -6.86 -6.88 -10.77 -12.17 -14.42 -42.43 -171.88 192.41
Return on Capital Employed (%) -5.14 -6.80 -6.78 -10.74 -12.13 -14.10 -20.15 -2.97 11.11
Return on Assets (%) -4.40 -4.86 -4.10 -5.95 -6.02 -6.25 -11.92 -2.40 8.89

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 1 1 1 1 1 1 0 0
Non Curr. Liab. 1 0 0
Curr. Liab. 0 1 1 1 1 1 0 1 1
Minority Int.
Equity & Liab. 1 1 1 1 1 1 1 1 1
Non Curr. Assets 0 0 0 0 0 0 1 1 1
Curr. Assets 1 1 1 1 1 1 0 0 0
Misc. Exp. not W/O
Total Assets 1 1 1 1 1 1 1 1 1

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 0 1 2
Other Income 0
Total Income 0 0 1 2
Total Expenditure 0 0 0 0 0 0 0 -1 -2
PBIDT 0 0 0 0 0 0 0 0 0
Interest
Depreciation
Taxation
Exceptional Items
PAT 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 0
Cash Fr. Inv.
Cash Fr. Finan. 0 0
Net Change 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-03 (%) 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%)
Promoter 16.56 16.56 16.56 16.58 16.58 16.58 16.58 16.58 16.58
Public 83.44 83.44 83.44 83.42 83.42 83.42 83.42 83.42 83.42
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 06 Jul 2021
Closure of Trading Window
This is to inform you that as per Companys Code of Conduct for Prohibition of Insider Trading framed pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 the Trading Window for dealing in Securities of the Company is closed for all Designated Employees (including Directors) of the Company from 1st July 2021 till end of 48 hours after the declaration of the financial results of the Company for the quarter ended 30th June 2021.

All Designated Employees (including Directors) of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of Trading Window.

We kindly request you to take on record of the same.
Tue, 06 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Muthukumar P
Designation :- Company Secretary and Compliance Officer
Tue, 06 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to the Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 we hereby enclosed the certificate received from Cameo Corporate Services Limited the registrar and Share transfer agent of our company for the quarter ended 30.06.2021.

Technical Scans View Details

No Scans Found

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%